Quarterly pharmacy formulary change notice

Similar documents
Effective for all members on August 1, 2017

The Medical Letter. on Drugs and Therapeutics

Quarterly pharmacy formulary change notice

Comparison of representative topical corticosteroid preparations (classified according to the US system)

Quarterly pharmacy formulary change notice

Step Therapy Requirements

Medication Policy Manual. Topic: Dupixent, dupilumab Date of Origin: March 10, Committee Approval: March 10, 2017 Next Review Date: May 2018

Quarterly pharmacy formulary change

Step Therapy Criteria 2019

Drug Class Literature Scan: Topical Steroids

Michigan Pharmacy and Therapeutics Committee September 9, 2014 at 6:00 PM Kellogg Center, East Lansing, Michigan

Quarterly pharmacy formulary change notice

Comparison of representative topical corticosteroid preparations (classified according to the US system)

Quarterly pharmacy formulary change notice

Pharmacy Benefit Determination Policy

Eucrisa. Eucrisa (crisaborole) Description

Quarterly pharmacy formulary change notice

Eucrisa. Eucrisa (crisaborole) Description

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

Step Therapy Requirements

The safety and effectiveness of Dupixent in pediatric patients have not been established (1).

BLUE SHIELD OF CALIFORNIA MARCH 2016 STANDARD DRUG FORMULARY CHANGES

Quarterly pharmacy formulary change notice

Quarterly pharmacy formulary change notice

Quarterly Pharmacy Formulary Change Notice

Quarterly pharmacy formulary change notice

See Important Reminder at the end of this policy for important regulatory and legal information.

AETNA BETTER HEALTH January 2017 Formulary Change(s)

See Important Reminder at the end of this policy for important regulatory and legal information.

AETNA BETTER HEALTH January 2017 Formulary Change(s)

Part D Pharmacy. An Independent Licensee of the Blue Cross Blue Shield Association ( )

2018 Step Therapy (ST) Criteria

Calgary Long Term Care Formulary

Calgary Long Term Care Formulary

High-Cost Drug Exclusions

Blue Cross and Blue Shield of Minnesota GenRx Formulary Updates

DEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL

CENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 3Q17 July August

TABLE OF CONTENTS (Click on a link below to view the section.)

Step Therapy Criteria (Criteria for Step Therapy-2 [ST-2] Drugs)

Amerigroup Washington, Inc. to conduct postservice reviews of certain modifiers and services

2017 Formulary Changes Year to Date

Clinical Policy: Dupilumab (Dupixent) Reference Number: ERX.SPA.49 Effective Date:

Children s Hospital Of Wisconsin

Updates to your prescription benefits

Dupixent (dupilumab)

Step Therapy Medications

Topical Immunomodulators

High-Cost Drug Exclusions

TABLE OF CONTENTS (Click on a link below to view the section.)

Pharmacologic Treatment of Atopic Dermatitis

Texas Children's Hospital Dermatology Service PCP Referral Guidelines- Atopic Dermatitis (AD)

Updates to your prescription benefits

Connecticut Medicaid P&T Meeting Minutes December 2, 2010

WellCare s South Carolina Preferred Drug List Update

Texas Prior Authorization Program Clinical Edit Criteria

San Francisco Health Plan (SFHP)

BlueLink TPA FlexRx Updates

ALLERGIC RHINITIS-NASAL

Alprazolam 0.25mg, 0.5mg, 1mg tablets

See Important Reminder at the end of this policy for important regulatory and legal information.

LABEL NAME CHANGE EFFECTIVE DATE ARCALYST 220 MG INJECTION

Quarterly pharmacy formulary change notice

Texas Prior Authorization Program Clinical Edit Criteria

TABLE OF CONTENTS (Click on a link below to view the section.)

Spending on Individuals with Type 1 Diabetes and the Role of Rapidly Increasing Insulin Prices

Health Partners Medicare Prime 2019 Formulary Changes

Drug Formulary Update, April 2017 Commercial and State Programs

Conversion from lantus to tresiba

Quarterly pharmacy formulary change notice

Clinical pharmacology review for primary health care providers: II. Steroids

ANTIEMETICS STEP. Step Therapy Requirements Effective April 1, 2019

Lantus levemir conversion

TABLE OF CONTENTS (Click on a link below to view the section.)

2015 Medicare Step Therapy Criteria. Last Modified: 12/31/2014 Last Submitted to CMS: 10/29/2014

84:00. Skin and Mucous Membrane Agents. 84:00 Skin and Mucous Membrane Agents

2017 Step Therapy (ST) Criteria

Drug Use Criteria: Exogenous Insulin Products

Insulin Prior Authorization with optional Quantity Limit Program Summary

Date: October 3, 2017 To: Participating Providers From: YourCare Health Plan Provider Relations Subject: 2018 Formulary Changes

2015 Step Therapy Prior Authorization Medical Necessity Guidelines

ADMELOG, NOVOLIN, NOVOLOG, and FIASP

PHARMA-MEDIC SERVICES INC. POLICY MANUAL

Kentucky Pharmacy and Therapeutics Advisory Committee meeting minutes Triton Park Blvd., Louisville, KY April 26, p.m.-3 p.m.

8/13/2016. Insulin Basics. Rapid-Acting Insulin Analogs. Current Insulin Products and Pens. Basal Insulin Analogs. History of Insulin Therapy

High-Cost Drug Exclusions

THERAPEUTIC AREA NAME STRENGTH DOSAGE FORM

Aetna Better Health of Illinois Medicaid Formulary Updates

Alameda Alliance for Health Pharmacy & Therapeutics (P&T) Committee Decisions

Calgary Zone LTC Formulary Autosubstitution List

Drug Effectiveness Review Project Summary Report Long acting Insulins

THERAPEUTIC AREA NAME STRENGTH DOSAGE FORM

Drugs That Require Step Therapy (ST)

Calgary Zone LTC Formulary Autosubstitution List

2018 Step Therapy (ST) Criteria

Alameda Alliance for Health Pharmacy & Therapeutics (P&T) Committee Decisions

Drugs That Require Step Therapy (ST)

Transcription:

Provider Bulletin June 2017 The formulary changes listed in the table below apply to all Anthem HealthKeepers Plus patients. These changes were reviewed and approved at the first quarter Pharmacy and Therapeutics Committee meeting held on March 29, 2017. Effective August 1, 2017, formulary changes, nonformulary changes and prior authorization requirements will apply. Therapeutic class LAMA and LAMA/LABA PRODUCTS THERAPY FOR ACNE ANTICOAGULANTS BETA AGONIST INHALERS BIPOLAR DISORDER DRUGS BIPOLAR DISORDER DRUGS Effective for all Anthem HealthKeepers Plus patients on August 1, 2017 Medication SPIRIVA 18 MCG CP-HANDIHALER DIFFERIN 0.1% GEL (OTC PRODUCT) COUMADIN TABLET (BRAND NAME ONLY) XOPENEX HFA INHALER EQUETRO CAPSULES Formulary status change WITH STEP THERAPY REVISE QL* 2 INHALER PER 30 WITH PRIOR AUTHORIZATION (PA) Potential alternatives (preferred products) SPIRIVA RESPIMAT 2.5 MCG INHALER SPIRIVA RESPIMAT 1.25 MCG INHALER WARFARIN TABLET JANTOVEN TABLET LITHIUM SOLUTION AFREZZA 90-4 UNIT AFREZZA 90-8 UNIT 6 BOXES PER 30 4 BOXES PER 30 The information in this bulletin may be an update or change to your provider manual. Find the most current manual at: https://mediproviders.anthem.com/va HealthKeepers, Inc. is an independent licensee of the Blue Cross and Blue Shield Association. ANTHEM is a registered trademark of Anthem Insurance Companies, Inc. The Blue Cross and Blue Shield names and symbols are registered marks of the Blue Cross and Blue Shield Association. AVAPEC-1458-17 June 2017

Page 2 of 5 METRONIDAZOLE PROGESTINS METRONIDAZOLE BASAGLAR 100 UNIT/ML KWIKPEN LANTUS 100 UNITS/ML VIAL LANTUS SOLOSTAR 100 UNITS/ML HUMALOG 100 UNITS/ML VIAL HUMALOG 100 UNITS/ML KWIKPEN HUMALOG 200 UNITS/ML KWIKPEN HUMALOG 100 UNITS/ML CARTRIDGE HUMALOG MIX 75-25 VIAL HUMALOG MIX 50-50 VIAL HUMALOG MIX 75-25 KWIKPEN HUMALOG MIX 50-50 KWIKPEN HUMULIN 70-30 VIAL HUMULIN N 100 UNITS/ML VIAL HUMULIN N 100 UNITS/ML KWIKPEN HUMULIN R 100 UNITS/ML VIAL HUMULIN 70/30 KWIKPEN LEVEMIR 100 UNITS/ML VIAL LEVEMIR FLEXTOUCH 100 UNITS/ML NOVOLOG 100 UNITS/ML FLEXPEN NOVOLOG 100 UNIT/ML VIAL NOVOLOG 100 UNIT/ML CARTRIDGE NOVOLOG MIX 70-30 VIAL NOVOLOG MIX 70-30 FLEXPEN SYRN NOVOLIN N 100 UNITS/ML VIAL NOVOLIN R 100 UNITS/ML VIAL NOVOLIN 70-30 100 UNIT/ML VIAL RELION NOVOLIN N 100 UNIT/ML RELION NOVOLIN R 100 UNIT/ML RELION NOVOLIN 70-30 VIAL HUMULIN R 500 UNITS/ML VIAL HUMULIN R 500 UNITS/ML KWIKPEN TOUJEO SOLOSTAR 300 UNITS/ML LIDOCAINE 5% LIDOCAINE 2% VISCOUS SOLN LIDOCAINE HCL 4% SOLUTION METRONIDAZOLE 1% GEL METRONIDAZOLE TOP 1% GEL PUMP HYDROXYPROGESTERONE 1.25 G/5ML MAKENA 1;250 MG/5 ML VIAL MAKENA 250 MG/ML VIAL LIDOCAINE HCL 4% SOLUTION LIDOCAINE 5% METRONIDAZOLE 1% GEL METRONIDAZOLE TOP 1% GEL PUMP HYDROCORTISONE 0.5% TRIAMCINOLONE ACETONIDE 0.5% TRIAMCINOLONE ACETONIDE 0.5% ADD QUANTITY LIMIT* (QL) 30 ML PER 30 REVISE QL* 21 ML PER 30 ADD QL 15 ML PER 30 5GMS PER DAY 10 GMS PER DAY WITH PA QL ADDED* 10 ML PER DAY QL REVISED* 5 GMS PER DAY 30 GMS PER 30

Page 3 of 5 ALCLOMETASONE DIPROPIONATE 0.05% ALCLOMETASONE DIPROPIONATE 0.05% HYDROCORTISONE BUTYRATE 0.1 % LOCOID 0.1% HYDROCORTISONE BUTYRATE 0.1 % LOCOID LIPO 0.1 % CLOBETASOL PROPIONATE 0.05% SOLUTION, NON-ORAL CORMAX 0.05% SOLUTION, NON-ORAL HALOBETASOL PROPIONATE 0.05 % ULTRAVATE 0.05 % HALOBETASOL PROPIONATE 0.05 % ULTRAVATE 0.05 % AMCINONIDE 0.1 % AMCINONIDE 0.1 % DESONIDE 0.05 % DESOWEN 0.05 % TRIDESILON 0.05 % DESONIDE 0.05 % LOTION DESOWEN 0.05 % LOTION DESONIDE 0.05 % DESOXIMETASONE 0.25 % TOPICORT 0.25 % DESOXIMETASONE 0.05 % GEL TOPICORT 0.05 % GEL DESOXIMETASONE 0.25 % TOPICORT 0.25 % DIFLORASONE DIACETATE 0.05 % PSORCON 0.05 % DIFLORASONE DIACETATE 0.05 % APEXICON E 0.05 % CUTIVATE 0.05 % FLUTICASONE PROPIONATE 0.05 % FLUTICASONE PROPIONATE 0.005 % HALOG 0.1 % HALOG 0.1 % PANDEL 0.1 % CLOCORTOLONE PIVALATE 0.1 % CLODERM 0.1 % DERMATOP 0.1 % PREDNICARBATE 0.1 % DERMATOP 0.1 % PREDNICARBATE 0.1 % FOAM OLUX 0.05 % FOAM 45G MS PER 30 50 GMS PER 30 60GMS PER 30 80GMS PER 30 90GMS PER 30 100GMS PER 30

Page 4 of 5 % % LOTION % LOTION TEMOVATE 0.05 % TEMOVATE 0.05 % CLOBETASOL E 0.05 % FLUOCINOLONE ACETONIDE 0.01 % SOLUTION, NON-ORAL SYNALAR 0.01 % SOLUTION, NON-ORAL FLUOCINOLONE ACETONIDE 0.01 % FLUOCINOLONE ACETONIDE 0.025 % SYNALAR 0.025 % FLUOCINOLONE ACETONIDE 0.025 % SYNALAR 0.025 % CAPEX SHAMPOO 0.01 % SHAMPOO FLUOCINONIDE 0.05 % FLUOCINONIDE 0.1 % VANOS 0.1 % HYDROCORTISONE VALERATE 0.2 % HYDROCORTISONE VALERATE 0.2 % FLUOCINONIDE 0.05 % SOLUTION, NON- ORAL FLUOCINONIDE 0.05 % GEL (GRAM) FLUOCINONIDE 0.05 % (GRAM) TRIANEX 0.05 % (GRAM) TRIAMCINOLONE ACETONIDE 0.025 % TRIAMCINOLONE ACETONIDE 0.1 % TRIDERM 0.1 % TRIAMCINOLONE ACETONIDE 0.025 % TRIAMCINOLONE ACETONIDE 0.1 % 120GMS PER 30 180 GMS PER 30 DAY 240 GMS PER 30 430 GMS PER 30 454 GMS PER 30

VAGINAL ESTROGENS VAGINAL ESTROGENS XANTHINES XANTHINES Anthem HealthKeepers Plus Page 5 of 5 YUVAFEM 10 MCG VAGINAL INSERT PREMARIN VAGINAL ELIXOPHYLLIN 80 MG/15 ML ELIX (BRAND ONLY) THEO-24 ER MG CAPSULES (BRAND ONLY) WITH STEP THERAPY * Indicates no changes in Preferred/Nonpreferred status revision or addition to UM edit only. YUVAFEM 10 MCG VAGINAL INSERT 80 MG/15 ML SOLN 80 MG/15 ML SOLN ER TABLETS What action do I need to take? Please review these changes and work with your Anthem HealthKeepers Plus patients to transition them to formulary alternatives. If you determine formulary alternatives are not clinically appropriate for specific patients, you will need to obtain prior authorization to continue coverage beyond the applicable effective date. What if I need assistance? We recognize the unique aspects of patients cases. If your Anthem HealthKeepers Plus patient cannot be converted to a formulary alternative, call our Pharmacy department at 1-800-901-0020 and follow the voice prompts for pharmacy prior authorization. You can find the preferred drug list (formulary) on our provider website at https://mediproviders.anthem.com/va. If you need assistance with any other item, contact your local Provider Relations representative or call Provider Services at 1-800-901-0020.